ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0

作者：

Besse, Benjamin ^{[1
]}

Mazieres, Julien ^{[2
]}

Ribassin-Majed, L. ^{[3
]}

Barlesi, Fabrice ^{[4
]}

Bennouna, Jaafar ^{[5
]}

Gervais, Radj ^{[6
]}

Moreau, Lionel

Berard, Henri ^{[7
]}

Debieuvre, Didier

Molinier, Olivier ^{[8
]}

Moro-Sibilot, Denis ^{[9
]}

Souquet, Pierre-Jean ^{[10
]}

Pignon, Jean-Pierre ^{[3
]}

Amour, Elodie ^{[11
]}

Celebic, A. ^{[3
]}

Morin, Franck ^{[11
]}

Milleron, Bernard ^{[11
]}

Zalcman, Gerard ^{[12
]}

Soria, Jean-Charles ^{[1
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France

[3] Gustave Roussy, Biostat, Villejuif, France

[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France

[5] Inst Cancerol Ouest, Gustave Roussy, France

[6] Ctr Francois Baclesse, Caen, France

[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France

[8] Le Mans Reg Hosp, Le Mans, France

[9] Unite Oncol Thorac Pneumol, Pierre Benite, France

[10] Pneumol Hcl, Paris, France

[11] Ifct, Paris, France

[12] Caen Univ Hosp, Caen, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO08.02

引用

页码：S301 / S301

页数：1

共 50 条

[21] A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation after Curative Resection for Stage I NSCLC with Primary Tumors Between 1-4 cm
Durm, G.
Birdas, T.
Liu, H.
Jalal, S.
Kesler, K.
Rieger, K.
Ceppa, D.
Hanna, N.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S257 - S258
[22] Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505
Wakelee, Heather A.
Dahlberg, Suzanne E.
Keller, Steven M.
Tester, William J.
Gandara, David R.
Graziano, Stephen L.
Adjei, Alex
Leighl, Natasha
Aisner, Seena C.
Rothman, Jan M.
Patel, Jyoti
Sborov, Mark D.
Mcdermott, Sean R.
Perez-Soler, Roman
Traynor, Anne M.
Butts, Charles
Evans, Tracey
Horn, Leora
Ramalingam, Suresh S.
Schiller, Joan
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S796 - S796
[23] TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
Soo, R.
De Marinis, F.
Han, J. -Y.
Ho, C. M. J.
Lin, Y.
Servidio, L.
Sandelin, M.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S272 - S272
[24] Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatinivinorelbine) - Treat
Kreuter, Michael
Vansteenkiste, Johan
Fischer, Juergen R.
Eberhardt, Wilfried
Zabeck, Heike
Kollmeier, Jens
Serke, Monika
Frickhofen, Norbert
Reck, Martin
-Riedel, Walburga Engel
Neumann, Silke
Thomeer, Michiel
Schumann, Christian
De Leyn, Paul
Greeter, Thomas
Stamatis, Georgios
Griesinger, Frank
Thomas, Michael
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[25] Adjuvant docetaxel plus cisplatin in stage I/II non-small cell lung cancer (NSCLC):: Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG).
Tomek, S
End, A
Klepetko, W
Csiszer, E
Csekeö, A
Kovacs, G
Gingrich, E
Balint, B
Francovszky, E
Zielinski, CC
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 690S - 690S
[26] Multicenter Observational Study of Patients with Resected Early-Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial
Hishida, Tomoyuki
Tsuboi, Masahiro
Yoh, Kiyotaka
Takamochi, Kazuya
Sakurai, Hiroyuki
Goto, Yasushi
Shukuya, Takehiro
Ohashi, Yasuo
Kunitoh, Hideo
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S653 - S654
[27] SELECT BIOMARKER ANALYSES OF COMPLETELY RESECTED NSCLC TUMORS FROM ENROLLED PATIENTS IN AN ADJUVANT ERLOTINIB (TARCEVA®) CLINICAL TRIAL (RADIANT)
Richardson, Frank
Richardson, Katherine
Young, David
Sennello, Regina
Horan, Julie
Davies, Angela
Crino, Lucio
Krzakowski, Maciej
Hoffman, Philip
Chang, Gee Chen
O'Orian, Mary
Kim, Hoon-Kyo
Cho, Eun Kyung
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S397 - S398
[28] ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized, placebo-controlled Phase II trial
Herbst, R
Johnson, B
Rowbottom, J
Fidias, P
Lu, C
Prager, D
Roubec, J
Csada, E
Dimery, I
Heymach, J
LUNG CANCER, 2005, 49 : S35 - S36
[29] A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC)
Karp, D. D.
Lee, S. J.
Wright, G. L. Shaw
Johnson, D. H.
Johnston, M. R.
Goodman, G. E.
Clamon, G. H.
Okawara, G. S.
Marks, R.
Ruckdeschel, J. C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[30] A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
Calvo, Virginia
Domine, Manuel
Sullivan, Ivana
Gonzalez-Larriba, Jose-Luis
Ortega, Ana Laura
Bernabe, Reyes
Sala, Maria Angeles
Campos, Begona
De Castro, Javier
Martin-Martorell, Paloma
Bosch-Barrera, Joaquim
Mielgo, Xabier
Vila, Laia
Casal, Joaquin
Ros, Silver
Aguillo, Maite Martinez
Padilla, Airam
Sandiego, Sergio
Machado, Jonathan Aires
Provencio-Pulla, Mariano
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →